B. Riley raised the firm’s price target on Capricor Therapeutics (CAPR) to $50 from $21 and keeps a Buy rating on the shares. The clinical data ...
The good news is that as 2025 comes to a close, the connection between astrology and numerology provides lucky breaks to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback